Entera Bio (ENTX) completes $275M Rule 506(b) private offering of shares and warrants
Rhea-AI Filing Summary
Entera Bio Ltd., an Israel-incorporated biotechnology company, reported a completed exempt securities offering under Regulation D Rule 506(b). The company sold $274,999,976 of securities, consisting of an aggregate of 122,961,215 Ordinary Shares and 11,842,695 pre-funded warrants, with no remaining amount to be sold. The first sale occurred on July 28, 2026. The offering involved equity, options/warrants, and the underlying ordinary shares, with multiple investment banks identified for sales compensation and no finders’ fees reported.
Positive
- $274,999,976 of securities successfully sold in an exempt private offering, materially strengthening Entera Bio Ltd.’s capital base.
- Offering fully subscribed with $0 remaining to be sold, indicating completion of the planned capital raise.
Negative
- None.
Filing Explained
The completed financing includes warrants whose exercise could further reduce existing holders’ percentage ownership.
The offering is reported as completed; the filing includes ordinary shares and pre-funded warrants, and exercise of the warrants would add shares and reduce existing holders’ percentage ownership absent offsetting changes.
A pre-funded warrant is sold at nearly the full share price with a nominal exercise price and converts to shares when exercised.
The notice does not state how the reported
The warrant line item has no disclosed exercise event or timing, so the filing does not date when that additional-share conversion would occur.
Key Figures
Total Amount Sold: $274,999,976 USD
Ordinary Shares in Offering: 122,961,215 shares
Pre-Funded Warrants: 11,842,695 warrants
+3 more
6 metrics
Total Amount Sold
$274,999,976 USD
Aggregate securities sold in the exempt offering
Ordinary Shares in Offering
122,961,215 shares
Ordinary Shares included in the aggregate offering amount
Pre-Funded Warrants
11,842,695 warrants
Pre-Funded Warrants included in the aggregate offering amount
Total Remaining to be Sold
$0 USD
Indicated remaining amount in the offering
Date of First Sale
2026-07-28
Initial sale date for securities in the offering
Finders’ Fees
$0 USD
Reported finders’ fees associated with the offering
Key Terms
Regulation D, Rule 506(b), Pre-Funded Warrants, covered securities, +1 more
5 terms
Regulation D regulatory
"Certifying that, if the issuer is claiming a Regulation D exemption"
Regulation D is a set of rules that govern how companies can raise money from investors without going through the full process required for public stock offerings. It provides simplified options for private placements, making it easier for companies to seek investments from a smaller group of investors. For investors, it offers opportunities to invest in private companies, often with fewer restrictions, but also with different levels of risk and disclosure.
Rule 506(b) regulatory
"X | Rule 506(b) | Rule 506(c) | Securities Act Section 4(a)(5)"
Rule 506(b) is a U.S. securities exemption that lets companies sell shares or debt privately without full public registration, provided sales are primarily to accredited investors, up to 35 non‑accredited but financially knowledgeable buyers, and there is no public advertising or solicitation. It matters to investors because offerings under 506(b) usually include less public disclosure than registered securities—like buying from a private seller rather than a retail store—so buyers must do more of their own fact‑checking and rely on their financial sophistication.
Pre-Funded Warrants financial
"Other (describe) | Pre-Funded Warrants, and underlying Ordinary Shares"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
covered securities regulatory
"if the securities that are the subject of this Form D are "covered securities""
Investment Company Act of 1940 regulatory
"Is the issuer registered as an investment company under the Investment Company Act of 1940?"
A U.S. federal law that sets the rulebook for pooled investment vehicles such as mutual funds, exchange-traded funds and similar money managers, requiring them to register with regulators, disclose holdings and fees, limit conflicts of interest, and follow governance standards. It matters to investors because these protections and transparency rules act like a referee and scoreboard, helping people compare funds, trust that managers follow fair practices, and spot hidden costs or risks.
Offering Details
private placement
Offering
Offering Type
private placement
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What amount did Entera Bio Ltd. (ENTX) raise in its exempt offering?
Entera Bio Ltd. raised $274,999,976 in an exempt offering. The amount reflects 122,961,215 Ordinary Shares and 11,842,695 pre-funded warrants sold, with no remaining amount indicated as available to be sold.
What securities did Entera Bio Ltd. (ENTX) offer in this Form D filing?
Entera Bio Ltd. offered equity, pre-funded warrants, and the ordinary shares underlying those warrants. The filing specifies an aggregate of 122,961,215 Ordinary Shares and 11,842,695 pre-funded warrants included in the total offering amount.
Under which exemption did Entera Bio Ltd. (ENTX) conduct this offering?
Entera Bio Ltd. conducted the offering under Rule 506(b) of Regulation D. This rule allows certain private offerings to accredited investors without SEC registration, subject to specific disclosure and solicitation limitations outlined in U.S. securities laws.
When did the first sale occur in Entera Bio Ltd.’s (ENTX) Form D offering?
The first sale in Entera Bio Ltd.’s exempt offering occurred on July 28, 2026. This date marks when investors first purchased securities in the private placement conducted under Rule 506(b) as disclosed in the Form D notice.
Did Entera Bio Ltd. (ENTX) report any finder’s fees in this offering?
Entera Bio Ltd. reported $0 in finder’s fees for this offering. While several investment banks are listed in the sales compensation section, the specific line for finders’ fees shows no cash compensation paid to third-party finders.
What industry and size characteristics does Entera Bio Ltd. (ENTX) report in this Form D?
Entera Bio Ltd. identifies as a biotechnology company in the health care industry. For issuer size, it chose the option to decline to disclose its revenue or aggregate net asset value range, rather than specifying a numerical band.